The Valley Desk

NCT05108922 · Interventional trial

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Overall registry status Completed

Phase 3

Conditions Alzheimer Disease, Mild Cognitive Impairment (MCI)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov